Medical Communications

The FDA has approved Regeneron’s Evkeeza (evinacumab-dgnb) as an adjunct to other low-density lipoprotein cholesterol (LDL-C) lowering therapies to treat …

The rheumatoid arthritis drug tocilizumab can reduce the risk of death in severe COVID-19 patients and shorten the time spent …

AI-driven pharma-tech company Exscientia has appointed Elizabeth Crain to their Board of Directors.

In the last week, a number of COVID-19 vaccine developments have been made. Johnson & Johnson’s one-shot jab was found …

Oxford University and AstraZeneca could release a new vaccine by October in order to counter the new mutations of COVID-19 …

Pfizer has withdrawn its application in India for emergency use authorisation of its vaccine, which it has produced with German …

Hyloris Pharmaceuticals and Purna Female Healthcare (PFH), a spin-off founded by Purna Pharmaceuticals and Creafund, have entered into a partnership …

AstraZeneca’s Imfinzi (durvalumab) has failed to improve overall survival (OS) for patients with recurrent or metastatic head and neck cancer …

Destiny Pharma, a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life threatening …

Raremark has appointed Caroline O’Connor as its new Chief Commercial Officer. Previously holding the position of Raremark’s Senior Vice President …

Scenic Biotech has announced the appointment of Dr Philippe Dro as its independent Chairman. Dr Dro replaces Dr Ulrich Grau, …

Most of Pharmafile.com’s top stories this week concern the approval of various treatments in the US, UK, and EU – …

Germany’s main public health body has recommended that AstraZeneca’s COVID-19 vaccine is only administered to those aged between 18 and …

Novavax has announced that its COVID-19 vaccine candidate, NVX-CoV2373, demonstrated an efficacy of 89.3% in its UK Phase III trial. …

Toxys, Leiden University, and Leiden University Medical Center have agreed to commercialise and develop further the ToxProfiler technology invented at …